Compare Expensify Inc (EXFY) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Revvity Inc — how do they compare? Expensify Inc trades at $1.79 (market cap $170.21M), while Revvity Inc trades at $111 (market cap $12.42B). The key difference: Revvity Inc is far larger — about 73× Expensify Inc's market cap, and Revvity Inc pays a 0.25% dividend while Expensify Inc pays none. Which is the better fit depends on your goals.
| EXFY | RVTY | |
|---|---|---|
Market Cap | $170.21M | $12.42B |
Sector | Technology | Technology |
52-Week High | $2.33 | $117.75 |
52-Week Low | $0.75 | $82.26 |
Enterprise Value | $109.24M | $14.91B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $1.755, down 3.04% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.04, beating expectations, but maintains negative profitability metrics with a -14.68% net income margin. Recent developments include AI-powered expense management expansions and a $25 million stock repurchase program, indicating strategic initiatives to drive growth.
The outlook remains cautious due to persistent unprofitability despite revenue stabilization around $140 million. Investment opportunities lie in operational efficiency gains and new product integrations, but risks include competitive pressure and the challenge of achieving sustainable profitability. Analyst sentiment is divided with equal buy/hold ratings, reflecting uncertainty about the company's turnaround potential.
RVTY trades at $110.99, down slightly by 0.2% today, near the analyst consensus price target of $111.43. The stock shows a bullish technical trend with recent earnings beats in Q3 2025, Q4 2025, and Q1 2026. Strong profitability metrics include a gross margin of 54.32% and net income margin of 8.26%. Recent news highlights AI integration advancements and FDA clearances, supporting growth prospects.
The outlook is positive with analyst consensus leaning buy (51.72%) and no sell ratings. Key risks include margin pressure and macroeconomic headwinds affecting cash flow, which turned negative in 2025 and 2026. The upcoming Q2 2026 earnings report on August 4, 2026, will be critical for validating current growth trajectory and investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
